Breast Cancer Trial, Recruiting NCT07262138 Sponsor: University of Pittsburgh Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT07262138
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 70 or older who have been diagnosed with invasive breast cancer and have not yet had surgery, drug treatments, or radiation therapy for this diagnosis (note: people whose invasive cancer was found after a biopsy done for an unrelated abnormality may also be included)
  • The breast cancer must have been found through a routine mammogram screening
  • The tumor must be 2cm or smaller, with no sign that cancer has spread to the lymph nodes, based on ultrasound or mammogram measurements — with specific grade requirements depending on size: tumors up to 1cm may be Grade I or Grade II; tumors between 1cm and 2cm must be Grade I only (confirm with trial site if unsure of your grade or size)
  • The breast cancer must test positive for estrogen receptors (ER+) and negative for the HER2 protein (HER2−), as confirmed by a local pathology laboratory using specific testing thresholds
  • People with cognitive impairment may be eligible, provided a legally authorised representative is able to sign the consent forms on their behalf
  • Stored tissue samples from a previous biopsy must be available and confirmed before registration

Who may not be able to join:

  • People who have already received any anti-cancer treatment — such as hormone therapy, chemotherapy, radiation, or an experimental therapy — for their current breast cancer diagnosis
  • People whose current breast cancer is considered by their treating doctor to be a recurrence of a previous cancer
  • People whose cancer is found in more than one area of the breast (multifocal or multicentric disease)
  • People with a history of a non-invasive cancer called DCIS in the other breast, or LCIS in either breast, or who have previously had radiation to the affected breast
  • People diagnosed with inflammatory breast cancer
  • Men with breast cancer
  • People with serious, uncontrolled medical conditions that their treating doctor believes would create unacceptable safety risks — this includes severe digestive or bowel conditions that affect the absorption of oral medications (such as uncontrolled Crohn's disease, ulcerative colitis, or chronic nausea, vomiting, or diarrhoea), or severe liver disease (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Priscilla F McAuliffe, MD, PhD, University of Pittsburgh

Phone: 412-266-1991

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 November 2025
Est. completion
1 November 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

12 month rate of tumor progression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov